GeneDx is trading 6% up at $69.01 in pre-market as investors position themselves ahead of the company's Q2 2026 earnings report.
- Analysts are forecasting $111.01 million in revenue and a $0.19 loss per share, with a focus on testing volumes and margin trends.
- The upward move also reflects a broader lift in U.S. index futures and improved risk sentiment across the market.